Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Bioequivalence of Julphar Insulin N vs Huminsulin Basal in Healthy Subjects
NCT02634528Phase 1Completed
- Sponsor
- Julphar
- Start
- Nov 2016
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin isophane in diabetes mellitus (DM) (2 arms), sponsored by Julphar. Primary endpoints: Area Under the Serum Insulin Concentration Curve from 0 to 24 hours and Maximum Observed Insulin Concentration at 24 hours. Started Nov 2016; status: completed.
02
Drugs
insulin isophane
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02634528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02634528.